The IPED (Investigation of Palpitations in the ED) Study (IPED)
Presyncope, Arrhythmias, Cardiac, Tachycardia, Supraventricular
About this trial
This is an interventional diagnostic trial for Presyncope focused on measuring pre syncope, palpitations
Eligibility Criteria
Inclusion Criteria:
- Participant aged 16 years or over
- Participant presenting with an episode of palpitations or pre-syncope
- Participant's underlying ECG rhythm during these episodes remains undiagnosed after clinical assessment.
Exclusion Criteria:
- Prior diagnostic ECG
- Palpitations or pre-syncope present during an admission ECG
- Frequent episodes (i.e. at least once a day)
- Participants under 16 years of age
- Previous participation in the study
- Inability or unwilling to give informed consent.
- Participants with recent (i.e. within 3 months) myocardial infarction, severe heart failure (NYHA class 4) or unstable angina
- Participants unwilling or unable to use the AliveCor Heart Monitor and AliveECG app
- Participants without a compatible smart phone or tablet
- Participants with cardiac pacemakers or other implanted electronic devices
- No telephone number for follow-up
- Participant in custody
Sites / Locations
- Royal Infirmary of Edinburgh
- Chesterfield
- Royal Devon and Exeter Hospital
- Leicester Royal Infirmary
- Royal London Hospital, Barts NHS Trust
- Whipps Cross Hospital, Barts NHS Trust
- Nottingham University Hospital
- Derriford Hospital
- Royal Berkshire Hospital
- Musgrove Park Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Study
Control
All STUDY arm participants will be given an AliveCor Heart Monitor and trained in the use of the device. They will be followed up at 90 days. If a participants allocated to the Study arm, gets an episode of palpitations or pre-syncope and is able to record an AliveCor Heart Monitor ECG during the episode, the participant will email the ECG recorded by the AliveCor app directly to the study team. The study team will review the ECG. If specialist follow-up is not required the study team will inform the participant of this and ask them to arrange general practitioner follow up. If the participant records a serious significant arrhythmia during the study period, the study team will alert the participant immediately and refer them to the cardiac electrophysiology service.
All CONTROL arm participants will receive no other intervention. Participants in both groups will be admitted, referred or discharged by the treating clinician according to current hospital protocols. Participants in both groups will be followed up at 90 days through hospital electronic patient record (EPR) systems and through a standardised written questionnaire and follow-up telephone call including symptoms and contact with medical services, satisfaction and compliance.